Blood Cancers Today: Recent Episodes
Blood Cancers Today
Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, live at the Eleventh Annual Meeting of the Society of Hematologic Oncology to discuss the phase III COMMANDS trial, the recent approval of luspatercept, and other developments in myelodysplastic syndromes (MDS) treatment and research.
Dr. Garcia-Manero spoke about the design of the phase III COMMANDS trial, which evaluated luspatercept versus epoetin alfa for the treatment of anemia in patients with lower-risk MDS who required red blood cell (RBC) transfusions but had not previously received an erythropoiesis-stimulating agent.
“The study is very interesting in that it's very well controlled … and the data [are] very clear,” he said.
The phase III trial showed 58.5% of patients receiving luspatercept achieved the primary endpoint of RBC transfusion independence for at least 12 weeks with a mean hemoglobin increase of at least 1.5 g/dL within the first 24 weeks, while this was only reported in 31.2% of patients receiving epoetin alfa.
Dr. Shadman of the Fred Hutchinson Cancer Center in Seattle rounds up the latest news in chronic lymphocytic leukemia (CLL) from the summer conferences, including updates on novel Bruton tyrosine kinase inhibitor (BTKi) therapies in CLL.
In this episode of The HemOnc Pulse, Dr. Bhatnagar, an Associate Professor of Medicine at the West Virigina University Cancer Institute, reflects on how the molecular characterization of acute myeloid leukemia (AML) has evolved. She joins host Chadi Nabhan, MD, MBA, FACP, to discuss how this growing base of knowledge has impacted diagnosis, treatment, and classification.
“The most significant changes have come about as a result of improvements and refinements in the molecular characterization of AML,” Dr. Bhatnagar said.
Some of these changes include major updates in the World Health Organization and European LeukemiaNet systems.
The episode also highlights Dr. Bhatnagar’s recent research, which explored the differential impact of mutations by race in patients with AML. While questions remain, she outlined future research that may help explain some disparities in AML outcomes.
Is there a venetoclax combination that reigns supreme in chronic lymphocytic leukemia (CLL)? Is venetoclax-based therapy the way to go in treating frontline CLL? Nitin Jain, MD, of the University of Texas MD Anderson Cancer Center, shares his thoughts on these questions and recent data published in the New England Journal of Medicine.
Dr. Nowakowski, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic, talks about the revolution in treatment options in diffuse large B-cell lymphoma(DLBCL).
"The last couple of years, we've seen quite a revolution in the treatment of DLBCL," he said. "We have multiple approved therapies now, and more coming, so it's really a very rapidly changing field."
He also discusses the five-year follow-up data from the L-MIND study, which evaluated tafasitamab in combination with lenalidomide.
Naveen Pemmaraju, MD, Associate Professor at the University of Texas MD Anderson Cancer Center, talks about the rare, ultrarare, and forgotten blood cancers, including his lifelong work in blastic plasmacytoid dendritic cell neoplasm (BPDCN), in this episode of The HemOnc Pulse.
Navneet Majhail, MD, MS, the Physician in Chief at Sarah Cannon in Nashville, Tennessee, delves into the intricacies of chimeric antigen receptor (CAR) T-cell therapy, discussing the logistics and challenges involved with these therapies.
Dr. Majhail explores strategies to improve access to CAR-T therapy and he discusses the role of CAR-T amidst the availability of bispecific antibodies as treatments for blood cancers.
Drs. Vijenthira and Prica, both of the Princess Margaret Cancer Centre, speak with host Chadi Nabhan, MD, MBA, FACP, about their analysis on the cost-effectiveness of pola-R-CHP and second-line CAR-T in patients with DLBCL, and why its results differed from a similar study published in the journal Blood in December 2022.
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma (MM), why he thinks certain approaches to minimal residual disease (MRD) in MM are “premature,” and the data that show why sustained MRD negativity is key, with host Chadi Nabhan, MD, MBA, FACP.
Alan Skarbnik, MD, of Novant Health, discusses treating patients with follicular lymphoma, the nuances involved in those decisions, and why bispecifics are here to stay, with host Chadi Nabhan, MD, MBA, FACP.
In this episode of The HemOnc Pulse, Amer Zeidan, MBBS, MHS, of Yale, discusses the impact of AML classification updates, the practical implications of testing for genetic alterations, and how patient characteristics inform his approach to treating AML, with host Chadi Nabhan, MD, MBA, FACP.
Swetha Kambhampati, MD, and Nikhil Thiruvengadam, MD, discuss the implications of their study investigating the cost-effectiveness of pola-R-CHP in previously untreated DLBCL.
In the latest episode of The HemOnc Pulse, Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil, a lymphoma specialist at Oxford Cancer and Haematology Centre, discusses the findings from the HoLISTIC Consortium, and what he thinks about checkpoint inhibitors upfront in the treatment of Hodgkin lymphoma.
What Keeps Michael Bishop, MD, Up at Night When it Comes to CAR-T?What is it about chimeric antigen receptor (CAR) T-cell therapies in hematologic oncology that keeps Michael Bishop, MD, Director of the Hematopoietic Stem Cell Transplantation Program at the University of Chicago, awake at night? In the latest episode of the podcast, Dr. Bishop discusses the matter and speaks about research that is identifying why CAR T-cell therapy doesn't always work.
In the latest episode of The HemOnc Pulse, Laurie H. Sehn, MD, MPH, Chair of the Lymphoma Tumour Group at the BC Cancer Centre for Lymphoid Cancer, talks with host Chadi Nabhan, MD, MBA, FACP, about which bispecific antibodies will change the game in follicular lymphoma treatment. Dr. Sehn also explains why the TRIANGLE study is anticipated to be practice-changing and how it may make upfront transplant obsolete in MCL.
Sanam Loghavi, MD, stops by The HemOnc Pulse and chats with host Chadi Nabhan, MD, MBA, FACP, about why she thinks 2022 was a major year for MDS in this latest episode of the podcast. With the unveiling of the two new MDS classification systems in the past year, Dr. Loghavi breaks down the classification models and what it means for the specialty.
In the latest episode of The HemOnc Pulse, podcast host Chadi Nabhan, MD, MBA, FACP, talks with Elizabeth Brem, MD, Associate Clinical Professor in the School of Medicine at the University of California, Irvine, off the heels of the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition. Dr. Brem tells us which chronic lymphocytic leukemia (CLL) abstracts cannot be ignored from ASH 2022, the latest news in Richter’s Transformation, and why she is moving away from ibrutinib in her own clinical practice.
Ruben Mesa, MD, President and Executive Director of the Atrium Health cancer service line (formerly the Executive Director of Mays Cancer Center), discusses his long career in myeloproliferative neoplasms (MPNs), the evolution of the disease, and what abstracts caught his attention at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.
Ruben Mesa, MD, President and Executive Director of the Atrium Health cancer service line (formerly the Executive Director of Mays Cancer Center), discusses his long career in myeloproliferative neoplasms (MPNs), the evolution of the disease, and what abstracts caught his attention at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.
In the inaugural episode of The HemOnc Pulse, podcast host Chadi Nabhan, MD, MBA, FACP, talks with Hagop Kantarjian, MD, and Elias Jabbour, MD, both of the Department of Leukemia at the University of Texas MD Anderson Cancer Center. The trio cover high-impact studies, novel treatment strategies, and controversial standard-of-care approaches for AML as well as ALL that were presented at the 2022 American Society of Hematology Annual Meeting & Exposition.